Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 6/20 | 0.42 |
| ▸ | CES1 | P23141 | 6/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CPS1 | P31327 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256756 | 0.81 | CES2 (0.43) | ALDH1A1ALOX15CES2CES1DGAT1 | |
| Water SCHEMBL27665336 | 0.79 | CES2 (0.42) | ALDH1A1ALOX15CES2CES1DGAT1 | |
| SCHEMBL165619 | 0.78 | CES2 (0.68) | ALDH1A1ALOX15CES2CES1NPC1 | |
| SCHEMBL4957103 | 0.77 | ALDH1A1 (0.54) | ALDH1A1ALOX15CES2CES1DGAT1 | |
| SCHEMBL9627405 | 0.77 | ALDH1A1 (0.54) | ALDH1A1ALOX15CES2CES1DGAT1 | |
| SCHEMBL645757 | 0.77 | ALDH1A1 (0.54) | ALDH1A1ALOX15CES2CES1NPC1 | |
| SCHEMBL14492919 | 0.76 | MEN1 (0.32) | CES2CES1KMT2A | |
| SCHEMBL25667839 | 0.76 | CES2 (0.39) | CES2CES1DGAT1 | |
| SCHEMBL31612915 | 0.75 | ALDH1A1 (0.52) | ALDH1A1ALOX15CES2CES1DGAT1 | |
| SCHEMBL16156066 | 0.75 | ALDH1A1 (0.52) | ALDH1A1ALOX15CES2CES1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2020-05-21 | — | — | US | disclosed |
| WO-2019147842-A1 | LIQUID CRYSTAL COMPOSITION CONTAINING A FIVE-MEMBERED HETEROCYCLIC RING, REVERSE-MODE POLYMER DISPERSED LIQUID CRYSTAL ELEMENT, AND ASSOCIATED SELECTIVELY DIMMABLE DEVICE | NITTO DENKO CORPORATION (JP) | 2019-08-01 | — | — | WO | disclosed |
| EP-2970106-B1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9512148-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512148-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | ALDH1A1 2724/4885ALOX15 4377/4885CES2 3521/4885 |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | CD22, BRDT, BCR | ALDH1A1 2724/4885ALOX15 4377/4885CES2 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.